Jingding Mulad Biopharmaceutical Technology Co., Ltd

Biomedical

Study experience: 19809-19835 Bachelor's degree in Clinical Medicine, Department of Medicine, Taipei Medical College 19929-19945 Master's degree in Pediatric Medicine, Institute of Clinical Medicine, Kaohsiung Medical College 19949-19973 Master's degree in Public Health, School of Public Health, Hopkins University, USA 19979-20015 Doctoral degree in Public Health, Hopkins University, USA Work experience: 199612 Distinguished Professor, Hawaii State University, USA 199704 Distinguished Professor, Johns Hopkinson University, USA 199907 National Institutes of Health, 2001 Zhongshan Executive Director of the University Biological Education Center 200212 Deputy Director of the Institute of Traditional Chinese Medicine at Capital Medical University 200310 Doctoral Supervisor of the School of Life Sciences at Jinan University 200606 Counselor of the United Nations Educational, Scientific and Cultural Organization 200609 Senior Advisor of the World Health Organization Southern Europe Cooperation Center 2009 Executive Director of Neox Biopharmaceutical Technology Co., Ltd. 201312 Nobel Prize winner Dr. Murad Vice Dean of the Institute of Translational Sciences 201510 Founder of the Jingding Great Health Industrial Park 2016 Dr. Smoot, Chairman of Taiwan Asia Biochemical Technology Co., Ltd., won the Nobel Prize in January 2017, and Dean of the Academy of Translational Sciences. On January 2018, a representative of Japan Kyoyang Corporation banned the Targeted Brain Hypothermia Project. Dr. Lin Hengyi, a representative of Asia Pacific Medical Technology Development Co., Ltd., signed a cooperation agreement for the "China Giant Deer Medical Device Manufacturing and Distribution Base" project. The total planned investment for the project is 250 million yuan. To build a medical device manufacturing and distribution base in our park, this project mainly involves the construction of the first Aike membrane machine (i.e. an extracorporeal membrane lung care machine) with independent intellectual property rights produced in China, and the construction and production of the world's first three-in-one Aike membrane medical device that stabilizes blood pressure and cools the temperature. 2、 The 6D targeted tumor treatment bed has been developed in collaboration with Taiwan's Zion Biotechnology Co., Ltd. The 6D targeted tumor treatment bed obtained the medical device license number issued by the US Food and Drug Administration in June 2019. The 6D targeted tumor treatment bed, designed with a six degree of freedom axis and equipped with an intelligent robotic arm, enables the treatment bed that carries patients to treat them in an automated process, improving the accuracy of cancer treatment, and reducing the medical harm caused by the human body during radiation therapy. The total investment of this project is planned to be 100 million yuan, covering an area of 2500 square meters and a total construction area of 4000 square meters. After the production of the 6D targeted tumor treatment bed project, the first domestically produced 6D targeted tumor treatment bed will be manufactured and produced in our park, breaking through the long-standing technical barriers faced by Europe, America, and Japan in China. The 6D targeted tumor treatment bed in this project can accelerate the speed and accuracy of cancer treatment and examination, thereby reducing the proportion of deaths among Chinese people due to cancer and tumor diseases, and achieving significant social benefits.